Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

NCT06411379 | Active Not Recruiting Phase 3 DMC FDA Drug

• 2 other identifiers: M1095-HS-302VELA-2
• Study Type: interventional
• Target: 418
• Locations: 12 countries
• Sites: 106

Brief Summary

This is a study to evaluate the clinical efficacy and safety of sonelokimab administered subcutaneously compared with placebo in the treatment of adult participants with moderate to severe hidradenitis suppurativa. Participants will be randomized 2:1 to either sonelokimab or matching placebo up to Week 16.

Conditions

Hidradenitis Suppurativa

Keywords

Hidradenitis Suppurativa; Hidradenitis; Sweat Gland Diseases; Skin Diseases; Skin Diseases, Bacterial; Suppuration; Anti-Inflammatory Agents; Sonelokimab; Nanobody; Apocrine Gland Disease

Outcome Measures

Primary Outcomes (1)

• Hidradenitis Suppurativa Clinical Response 75

  Percentage of participants achieving Hidradenitis Suppurativa Clinical Response 75 (HiSCR75), where HiSCR75 is defined as at least a 75% reduction from baseline in abscess and inflammatory nodule (AN) count, with no increase from baseline in abscess or draining fistula count.

  Week 16

Secondary Outcomes (6)

• Hidradenitis Suppurativa Clinical Response 50 (HiSCR50)

  Week 16

• Change in International Hidradenitis Suppurativa Severity Score System

  Week 16

• Dermatology Life Quality Index (DLQI)

  Week 16

• Reduction from Numerical Rating Scale (NRS30 & NRS50) in Patient's Global Assessment of Skin Pain (PGA Skin Pain)

  week 16

• Patient Global Impression - Severity of Illness - Hidradenitis Suppurativa at Week 16

  Week 16

Study Arms (2)

sonelokimab

EXPERIMENTAL

Subjects randomized to this arm will receive sonelokimab 120 mg Q2W from Weeks 0 to 6 then 120 mg Q4W starting at Week 8 up to Week 48.

Drug: Sonelokimab

Placebo

PLACEBO COMPARATOR

Subjects randomized to this arm will receive placebo Q2W from Weeks 0 to 6 then Q4W starting at Week 8 up to Week 16. They will receive sonelokimab 120 mg Q2W for 4 doses from Weeks 16 to 22 then Q4W from Week 24 up to Week 48

Drug: Placebo

Interventions

Sonelokimab DRUG

Sonelokimab

sonelokimab

Placebo DRUG

Placebo

Placebo

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Participants must be at least 18 years of age at the time of signing the informed consent.
• Participants who are diagnosed with hidradenitis suppurativa as determined by the investigator and have a history of signs and symptoms of hidradenitis suppurativa for at least 6 months before signing the informed consent.
• Participants who have had an inadequate response to appropriate systemic antibiotics for treatment of hidradenitis suppurativa (or demonstrated intolerance to, or had a contraindication to, systemic antibiotics for treatment of their HS), in the investigator's opinion.
• Participants who have a total AN count of ≥5.
• Participants who have HS lesions present in ≥2 distinct anatomical areas, at least one of which must contain single or multiple fistulas (ie, be Hurley Stage II or III).

You may not qualify if:

• Participants with a known hypersensitivity to sonelokimab or any of its excipients.
• Participants with any other active skin disease or condition that may, in the opinion of the investigator, interfere with the assessment of HS.
• Participants with underlying conditions that, in the opinion of the investigator, potentially places the participant at unacceptable risk.
• Participants with current severe or uncontrolled disease(s) that put(s) the participant at increased risk in the investigator's opinion, would preclude the participant from adhering to the protocol or completing the study per protocol.
• Participants with any other known autoimmune disease or any medical condition that in the opinion of the investigator would interfere with an accurate assessment of clinical symptoms of HS.
• Participants with a gastrointestinal condition including inflammatory bowel disease or diagnosis of ulcerative colitis or Crohn's disease.

Sponsors & Collaborators

• MoonLake Immunotherapeutics AG: lead

Study Sites (106)

Clinical Site

Birmingham, Alabama, 35244, United States

Location

Clinical Site

North Little Rock, Arkansas, 72117, United States

Location

Clinical Site

Fountain Valley, California, 92708, United States

Location

Clinical Site

Santa Monica, California, 90404, United States

Location

Clinical Site

Aventura, Florida, 33180, United States

Location

Clinical Site

Hialeah, Florida, 33012, United States

Location

Clinical Site

Miami, Florida, 33136, United States

Location

Clinical Site

Ocala, Florida, 34470, United States

Location

Clinical Site

Tampa, Florida, 33613, United States

Location

Clinical Site

Skokie, Illinois, 60077, United States

Location

Clinical Site

Plainfield, Indiana, 46168, United States

Location

Clinical Site

Murray, Kentucky, 42071, United States

Location

Clinical Site

Baton Rouge, Louisiana, 70809, United States

Location

Clinical Site

Baltimore, Maryland, 21287, United States

Location

Clinical Site

Ann Arbor, Michigan, 48109-5314, United States

Location

Clinical Site

Canton, Michigan, 48187, United States

Location

Clinical Site

Clarkston, Michigan, 48346, United States

Location

Clinical Site

Waterford, Michigan, 48328, United States

Location

Clinical Site

New Brighton, Minnesota, 55112, United States

Location

Clinical Site

Omaha, Nebraska, 68144, United States

Location

Clinical Site

Las Vegas, Nevada, 89145, United States

Location

Clinical Site

New York, New York, 10003, United States

Location

Clinical Site

Fargo, North Dakota, 58103, United States

Location

Clinical Site

Columbus, Ohio, 43213, United States

Location

Clinical Site

Murfreesboro, Tennessee, 37130, United States

Location

Clinical Site

Dallas, Texas, 75390-8565, United States

Location

Clinical Site

Plano, Texas, 75025, United States

Location

Clinical Site

San Antonio, Texas, 78213, United States

Location

Clinical Site

Morgantown, West Virginia, 26505, United States

Location

Clinical Site

Milwaukee, Wisconsin, 53226, United States

Location

Clinical Site

Ghent, 9000, Belgium

Location

Clinical Site

Leuven, 3000, Belgium

Location

Clinical Site

Liège, 4000, Belgium

Location

Clinical Site

Woluwe-Saint-Lambert, 1200, Belgium

Location

Clinical Site

Sofia, 1431, Bulgaria

Location

Clinical Site

Sofia, 1463, Bulgaria

Location

Clinical Site

Sofia, 1510, Bulgaria

Location

Clinical Site

Sofia, 1606, Bulgaria

Location

Clinical Site

Stara Zagora, 6003, Bulgaria

Location

Clinical Site

Calgary, Alberta, T3E 0B2, Canada

Location

Clinical Site

Edmonton, Alberta, T6G 1C3, Canada

Location

Clinical Site

Guelph, Ontario, N1L 0B7, Canada

Location

Clinical Site

Peterborough, Ontario, K9J 5K2, Canada

Location

Clinical Site

Richmond Hill, Ontario, L4B 1A5, Canada

Location

Clinical Site

Toronto, Ontario, M4E 1R7, Canada

Location

Clinical Site

Windsor, Ontario, N8W 1E6, Canada

Location

Clinical Site

Saskatoon, Saskatchewan, S7K 2C1, Canada

Location

Clinical Site

Ostrava, 708 52, Czechia

Location

Clinical Site

Prague, 110 00, Czechia

Location

Clinical Site

Prague, 15006, Czechia

Location

Clinical Site

Antony, 92160, France

Location

Clinical Site

Besançon, 25030, France

Location

Clinical SIte

Brest, 29200, France

Location

Clinical Site

Dijon, 21000, France

Location

Clinical Site

Le Mans, 72037, France

Location

Clinical Site

Lyon, 69003, France

Location

Clinical Site

Montpellier, 34295, France

Location

Clinical Site

Rouen, 76031, France

Location

Clinical Site

Saint-Mandé, 94160, France

Location

Clinical Site

Saint-Priest-en-Jarez, 42270, France

Location

Clinical Site

Toulouse, 31400, France

Location

Clinical Site

Augsburg, 86179, Germany

Location

Clinical Site

Bad Bentheim, 48455, Germany

Location

Clinical Site

Berlin, 10117, Germany

Location

Clinical Site

Bielefeld, 33647, Germany

Location

Clinical Site

Bochum, 44791, Germany

Location

Clinical Site

Bramsche, 49565, Germany

Location

Clinical Site

Darmstadt, 64283, Germany

Location

Clinical Site

Dresden, 01307, Germany

Location

Clinical Site

Gera, 07548, Germany

Location

Clinical Site

Hamburg, 20246, Germany

Location

Clinical Site

Kiel, 24105, Germany

Location

Clinical Site

Lübeck, 23538, Germany

Location

Clinical Site

Würzburg, 97080, Germany

Location

Clinical Site

Dublin, D04 T6F4, Ireland

Location

Clinical Site

Rotterdam, 3015 GD, Netherlands

Location

Clinical Site

Chorzów, 41-500, Poland

Location

Clinical Site

Katowice, 40-611, Poland

Location

Clinical Site

Kielce, 25-316, Poland

Location

Clinical Site

Olsztyn, 10-229, Poland

Location

Clinical Site

Poznan, 61-731, Poland

Location

Clinical Site

Szczecin, 70-332, Poland

Location

Clinical Site

Warsaw, 02-953, Poland

Location

Clinical Site

Wroclaw, 50566, Poland

Location

Clinical Site

Trnava, 91702, Slovakia

Location

Clinical Site

Alcorcón, 28922, Spain

Location

Clinical Site

Alicante, 03010, Spain

Location

Clinical Site

Badalona, 08916, Spain

Location

Clinical Site

Barcelona, 08003, Spain

Location

Clinical Site

Barcelona, 08036, Spain

Location

Clinical Site

Barcelona, 08041, Spain

Location

Clinical Site

Cadiz, 11009, Spain

Location

Clinical Site

Córdoba, 14004, Spain

Location

Clinical Site

Granada, 18012, Spain

Location

Clinical Site

Granada, 18014, Spain

Location

Clinical Site

Granollers, 08402, Spain

Location

Clinical Site

Madrid, 28006, Spain

Location

Clinical Site

Madrid, 28007, Spain

Location

Clinical Site

Madrid, 28041, Spain

Location

Clinical Site

Madrid, 28046, Spain

Location

Clinical Site

Manises, 46940, Spain

Location

Clinical Site

Málaga, 29010, Spain

Location

Clinical Site

Santiago de Compostela, 15706, Spain

Location

Clinical Site

Seville, 41009, Spain

Location

Clinical Site

Valencia, 46014, Spain

Location

Clinical Site

Valencia, 46026, Spain

Location

MeSH Terms

Conditions

Hidradenitis Suppurativa; Hidradenitis; Sweat Gland Diseases; Skin Diseases; Skin Diseases, Bacterial; Suppuration

Interventions

sonelokimab

Condition Hierarchy (Ancestors)

Bacterial Infections; Bacterial Infections and Mycoses; Infections; Skin Diseases, Infectious; Skin and Connective Tissue Diseases; Inflammation; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Officials

• Prof Kristian Reich, M.D., Ph.D. (equ.)

  MoonLake Immunotherapeutics AG

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, CARE PROVIDER
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 8, 2024
• First Posted: May 13, 2024
• Study Start: May 14, 2024
• Primary Completion: June 17, 2025
• Study Completion (Estimated): June 17, 2026
• Last Updated: May 21, 2025

Record last verified: 2025-05

Locations

ES (21); BU (5); DE (13); NL (1); US (30); PL (8); SL (1); BE (4); CA (8); FR (11); IE (1); CZ (3)